BlackRock holds 12.8% of ANI Pharmaceuticals

ANI Pharmaceuticals Inc. is reported to have a significant shareholder, as BlackRock, Inc. has filed an amended beneficial ownership report.

Rhea-AI Filing Summary

ANI Pharmaceuticals Inc. is reported to have a significant shareholder, as BlackRock, Inc. has filed an amended beneficial ownership report. BlackRock’s reporting business units collectively beneficially own 2,899,843 shares of ANI Pharmaceuticals common stock, representing 12.8% of the outstanding class.

BlackRock reports sole voting power over 2,860,943 shares and sole dispositive power over 2,899,843 shares, with no shared voting or dispositive power. Various clients and other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of ANI’s outstanding common stock.

Key Figures

Beneficially owned shares: 2,899,843 shares Percent of class: 12.8 % Sole voting power: 2,860,943 shares +3 more

6 metrics

Beneficially owned shares 2,899,843 shares Common stock of ANI Pharmaceuticals reported by BlackRock’s business units

Percent of class 12.8 % Portion of ANI Pharmaceuticals common stock beneficially owned by BlackRock

Sole voting power 2,860,943 shares Shares of ANI Pharmaceuticals over which BlackRock has sole voting authority

Shared voting power 0 shares ANI Pharmaceuticals shares with shared voting power reported by BlackRock

Sole dispositive power 2,899,843 shares ANI Pharmaceuticals shares over which BlackRock can solely direct disposition

Shared dispositive power 0 shares ANI Pharmaceuticals shares with shared dispositive power reported by BlackRock

Key Terms

beneficially owned, dispositive power, Schedule 13G, parent holding company, +1 more

5 terms

beneficially owned financial

"this reflects the securities beneficially owned, or deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

dispositive power financial

"Sole power to dispose or to direct the disposition of: 2899843"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"Ownership of more than 5 Percent on Behalf of Another Person."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

parent holding company financial

"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"

percent of class financial

"Percent of class: 12.8 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of ANI Pharmaceuticals (ANIP) does BlackRock currently report owning?

BlackRock’s reporting business units beneficially own 12.8% of ANI Pharmaceuticals’ common stock. This corresponds to 2,899,843 shares, making BlackRock a major institutional holder but filed on a passive Schedule 13G/A basis rather than an activist Schedule 13D.

How many ANI Pharmaceuticals (ANIP) shares does BlackRock report as beneficially owned?

BlackRock reports beneficial ownership of 2,899,843 shares of ANI Pharmaceuticals common stock. These shares are held across certain BlackRock business units whose holdings are aggregated for this filing, while other disaggregated units’ positions are not included here under SEC Release No. 34-39538.

What voting power does BlackRock have over ANI Pharmaceuticals (ANIP) shares?

BlackRock reports sole voting power over 2,860,943 shares of ANI Pharmaceuticals and no shared voting power. This means BlackRock alone can vote those shares or direct how they are voted, within its fiduciary role to underlying clients and funds.

What dispositive power does BlackRock report over ANI Pharmaceuticals (ANIP) stock?

BlackRock has sole dispositive power over 2,899,843 shares of ANI Pharmaceuticals and no shared dispositive power. Sole dispositive power means it can decide whether and how to sell or otherwise dispose of those shares on behalf of its clients.

Do any individual BlackRock clients own more than 5% of ANI Pharmaceuticals (ANIP)?

The filing states that various persons have rights to dividends or sale proceeds from ANI shares, but that no single person’s interest in ANI Pharmaceuticals common stock exceeds five percent of the company’s total outstanding common shares.

What type of SEC filing did BlackRock make regarding ANI Pharmaceuticals (ANIP)?

BlackRock submitted an Amendment No. 13 to Schedule 13G for ANI Pharmaceuticals. A Schedule 13G is a beneficial ownership report generally used by institutional investors taking a passive stake exceeding five percent of a public company’s shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:26 PM Accepted by SEC EDGAR 07/27/2026 - 04:25 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 13)

ANI PHARMACEUTICALS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00182C103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00182C103

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,860,943.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,899,843.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,899,843.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

12.8 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ANI PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 104 Carnegie Center Drive, Suite 300 Princeton NJ 08540
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 00182C103
Item 4.	Ownership
(a)	Amount beneficially owned: 2899843
(b)	Percent of class: 12.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2860943
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2899843
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of ANI PHARMACEUTICALS INC. No one person's interest in the common stock of ANI PHARMACEUTICALS INC is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/27/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7